#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Burkitt's lymphoma refractory Small cell lung cancer Diffuse large B-cell lymphoma recurrent Cutaneous T-cell lymphoma stage I Myeloproliferative neoplasm Antiphospholipid antibodies Sickle cell anaemia Familial dilated cardiomyopathy Dupuytren's contracture Hypersensitivity pneumonitis Pseudoxanthoma elasticum X-linked lymphoproliferative syndrome Gastrointestinal neuroendocrine tumour Haemophilia Leber's congenital amaurosis More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia Basal cell naevus syndrome – Trials in Disease Castleman’s disease – Life with Disease Cystic fibrosis lung – Trials in Disease Usher’s syndrome Brain stem glioma – Treatment Erdheim-Chester disease – Life with Disease Optic glioma – Life with Disease Cholangitis sclerosing Factor IX deficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vibozilimod Ficlatuzumab Ferrous Sulfate Purified Egg Phospholipids Etrasimod Arginine Transpocart19 Mercaptamine Olaparib Phenylalanine LTX-002 SODIUM Dorocubicel Onasemnogene Abeparvovec ZALFERMIN VX-993 Tulisokibart Camphor Formoterol Fumarate Dihydrate ANTI-GD2-800CW Sulfonamides, Urea Derivatives Alanine More therapies…

    Learn about Your Condition

    HER2 positive breast cancer Nephrogenic anaemia Periarthritis Pelvic venous thrombosis Diarrhoea Polycystic ovarian syndrome Combined immunodeficiency Neurotrophic keratopathy Renal cancer Parkinson's disease Breast neoplasm Laryngeal cancer stage II Glomerulonephritis chronic Cardiomyopathy B-cell type acute leukaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

EGFR gene mutation

  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Investigated Diseases:
    • Gastrointestinal carcinoma
    • Malignant neoplasm of ampulla of Vater
    • Salivary gland cancer
    Investigated Drugs:
    • 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    • Bay 2927088
    • SEVABERTINIB
    Denmark France Italy Spain

  • Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    • Bay 2927088
    • SEVABERTINIB
    Austria Belgium Bulgaria Czechia Denmark Finland +12

  • Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zirconium (89Zr) Patritumab Deruxtecan
    • Patritumab Deruxtecan
    The Netherlands

  • Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • EGFR gene mutation
    • Non-small cell lung cancer
    Investigated Drugs:
    • Lazertinib
    • Amivantamab
    • Bevacizumab
    France Italy The Netherlands Spain

  • Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Osimertinib
    Lithuania Norway Sweden

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!